Addendum to the Early Access Agreement (as defined below)Early Access Agreement • November 16th, 2015 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
WHEREAS on August 3, 2015, IMPATIENTS N.V. (dba “myTomorrows”) a company formed and registered under the laws of the Netherlands, and located at Pilotenstraat 45, 1059 CH, Amsterdam, The Netherlands (hereinafter “myT”) and Hemispherx Biopharma, Inc. located at 1617 JFK Blvd, Philadelphia, PA 19103 (hereinafter “HEB”), each a “Party” and together the “Parties” entered into an early access agreement to make Ampligen available in a specific Territory under an Early Access Program (“EAP”), the “Early Access Agreement”, and
EARLY ACCESS AGREEMENTEarly Access Agreement • November 16th, 2015 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances)
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 3rd day of August, 2015, (“Effective Date”) by and between
